Skip to content


  • Meeting abstract
  • Open Access

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura

Allergy, Asthma & Clinical Immunology20128 (Suppl 1) :A23

  • Published:


  • Severe Allergic Reaction
  • Dominant Lymph Node
  • Reactive Lymphoid Hyperplasia
  • Subcutaneous Immunoglobulin
  • Intractable Headache


Immune thrombocytopenia purpura (ITP) can co-exist with primary immunodeficiencies. Intravenous immunoglobulin (IGIV) therapy is an effective treatment. Subcutaneous immunoglobulin (SCIG) formulations that can be home-delivered have recently been developed. We describe 2 cases of pediatric ITP associated with hypogammaglobulinemia, treated with SCIG.

Case description

Case 1

A 14-year old male presented with a symptomatic thrombopenia. Infusions of IGIV led to an immediate improvement in platelet count. However, he experienced post-infusion intractable headaches, nausea and vomiting, which recurred after subsequent infusions. Intravenous anti-D therapy resulted in a severe allergic reaction. Short course prednisone protocol was implemented for symptomatic episodes. Preliminary blood work for splenectomy revealed low IgG level. The patient was put on SCIG replacement therapy (116 mg/kg/week). He experienced only one relapse since, which remained corticoresponsive.

Case 2

A 14-year-old male was referred for asymptomatic thrombo-neutropenia. Extensive work-up was normal. He was administered IVIG after which the platelet count quickly normalized. Eighteen months later, he developed monoarthritis and generalized adenopathies. Dominant lymph node biopsy showed reactive lymphoid hyperplasia. The patient started to experience recurrent thrombopenia flare-ups, needing monthly IVIG. Laboratory results indicated low IgM and IgG levels. To prevent further episodes, he received prophylactic monthly IVIG for 6 months before switching to SCIG (135 mg/kg/week). Platelet and also neutrophil levels normalized, which was not achieved with IGIV.

In both patients, SCIG therapy was well-tolerated with no adverse events occurring.


These results suggest that SCIG can be an effective and convenient treatment of pediatric ITP.

Authors’ Affiliations

Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec, Canada, H3T 1C5
Department of Microbiology and Immunology, Université de Montréal, Montréal, Québec, Canada, H3T 1J4
Department of Microbiology and Immunology, CHU Sainte-Justine, Montréal, Québec, Canada, H3T 1C5


© Chapdelaine et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.